Entering the U.S. market with a new product and brand name only four years ago, EOS imaging has admirably and substantially increased its mindshare in the medical imaging community. The market's adoption of the EOS system has continued to gain momentum, with more than 20 installations in the U.S., including some of the most prestigious healthcare institutions. EOS imaging is one of the Deloitte 2013 Technology Fast 50 laureate companies."EOS imaging's growth in the U.S. market is in line with the company's achievements in Europe and numerous early successes and promising near-term prospects in several markets, including Japan, Singapore and China," noted Daher. "This universal acknowledgment of EOS imaging's technology and product value validates the value the company brings to the fields of radiology and orthopedics, and the broader imaging community." Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leverage leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which, in turn, increases customer acquisition and overall market penetration potential. Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry. About EOS imaging EOS imaging designs, develops, and markets EOS®, a revolutionary and patented medical imaging system, based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Company is authorized to market the system in 31 countries, including the United States (FDA), Japan, Canada, Australia and the European Union (EU). Backed by an installed base of over 71 sites and more than 400,000 imaging sessions, EOS® benefits from worldwide recognition within the global medical community. As of December 31, 2012 the Group posted 2012 consolidated revenue of €9.42 million and employs 70 people including an R&D team of 25 engineers. The Group is based in Paris and holds three subsidiaries in Cambridge ( Massachusetts), in Canada at Montreal and in Germany, and offices in Singapore. EOS imaging is listed on Compartment C of the NYSE Euronext Paris ISIN: FR0011191766 – Ticker: EOSI Next press release: Annual results 2013 on January 22, 2014 (after market) About Frost & Sullivan Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.